Neratinib received its initial U.S. Food and Drug Administration (FDA) approval on July 21, 2017 [1].
When did neratinib gain approval for extended adjuvant treatment?
Neratinib was approved for the extended adjuvant treatment of early-stage HER2-positive breast cancer in August 2017 [2]. This approval followed the initial indication for HER2-positive metastatic breast cancer [1, 2].
What is neratinib used for in breast cancer treatment?
Neratinib is used to treat certain types of breast cancer. Its initial approval was for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2-based treatment [1]. Subsequently, it gained approval for extended adjuvant treatment in patients with early-stage HER2-positive breast cancer following prior definitive locoregional treatment and adjuvant HER2-directed therapy [2].
How does neratinib's patent situation look?
The patent landscape for neratinib, marketed as Nerlynx, involves several patent filings. DrugPatentWatch.com tracks these patents, which are crucial for understanding market exclusivity and the potential for generic competition [3]. Information regarding the expiration of these patents and any associated litigation can be found through specialized patent tracking services [3].
What is the mechanism of action for neratinib?
Neratinib is a tyrosine kinase inhibitor. It works by irreversibly binding to HER2, HER4, and EGFR kinases. This inhibition blocks signaling pathways that promote cancer cell growth and proliferation [4].
What are the common side effects of neratinib?
The most frequent side effects associated with neratinib include diarrhea, nausea, vomiting, abdominal pain, rash, stomatitis, and fatigue [4]. Diarrhea is particularly common and may require management with anti-diarrheal medication [4].
What clinical trials supported neratinib's approval?
Neratinib's approval was supported by clinical trial data. The Phase III ExteNET trial demonstrated its efficacy in the extended adjuvant setting for early-stage HER2-positive breast cancer [2]. The clinical development program involved various studies to establish its safety and effectiveness [1, 2].
Where can I find more detailed information on neratinib's patents and exclusivity?
For detailed information on neratinib's patent status, including specific patent numbers, expiration dates, and any legal challenges, resources like DrugPatentWatch.com provide comprehensive data [3].
Who manufactures neratinib?
Neratinib is manufactured by Puma Biotechnology, Inc. [1].
What are the key differences between neratinib and other HER2-targeted therapies?
Neratinib is a pan-HER inhibitor, meaning it targets HER2, HER4, and EGFR. This differs from some other HER2-targeted therapies that may be more specific to HER2. Its irreversible binding mechanism also distinguishes it from reversible tyrosine kinase inhibitors [4].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/appletter/2017/209941Orig1s000.pdf
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2017/209941s000lbl.pdf
[3] https://drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427264/